Regeneron Pharmaceuticals, Inc Patent Portfolio Statistics

tip_user1

Regeneron Pharmaceuticals, Inc.

Profile Summary

This article summarizes the perfomance of the assignee in the recent years. The overall statistics for this portfolio help to analyze the areas where the assignee is performing well. The filing trend, perfomance across the tech centers and the perfomance of the recent applications has been mentioned below. All the stats are calculated based on the perfomance in USPTO.

How does the overall patent portfolio of Regeneron Pharmaceuticals, Inc. look like?

Assignee Art Units
Total Applications: 1,362 1,242,188
Granted Patents: 747 573,607
Grant Index 76.15% ↑ 65.27%
Abandoned/Rejected Applications: 234 (23.85%) 305,215 (34.73%)
In-Process Applications: 370 363,366
Average Grant Time: 2.54 Years ↓ 2.92 Years
Average Office Actions: 1.71 ↓ 1.76

Which Technology Area Regeneron Pharmaceuticals, Inc. is filing most patents in? (Last 10 years)

Art Unit Definition Total Applications
1647 Immunology, Receptor/Ligands, Cytokines Recombinant Hormones, and Molecular Biology 215
1632 Molecular Biology, Bioinformatics, Nucleic Acids, Recombinant DNA and RNA, Gene Regulation, Nucleic Acid Amplification, Animals and Plants, Combinatorial/ Computational Chemistry 205
1646 Immunology, Receptor/Ligands, Cytokines Recombinant Hormones, and Molecular Biology 148
1633 Molecular Biology, Bioinformatics, Nucleic Acids, Recombinant DNA and RNA, Gene Regulation, Nucleic Acid Amplification, Animals and Plants, Combinatorial/ Computational Chemistry 143
Opap Parked GAU 118

How many patents are Regeneron Pharmaceuticals, Inc. filing every year?

Year Total Applications Predicted
2022 0* 822
2021 61* 626
2020 145 587
2019 155 155
2018 161 –
2017 124 –
2016 100 –
2015 115 –
2014 82 –
2013 86 –

*The drop in the number of applications filed in last two years compared to previous years is because applications can take up to 18 months to get published

Recently filed patent applications of Regeneron Pharmaceuticals, Inc. in USPTO?

Publication number: None
Application number: 17/618,061

Abstract:
–

Publication date: –
Applicant: Regeneron Pharmaceuticals, Inc.
Inventors: Andrew Tustian

Publication number: US20220089711A1
Application number: 17/537,275

Abstract:
The present invention provides methods and compositions for treating or preventing atherosclerosis in a subject. The methods of the present invention comprise administering an inhibitor of angiopoietin-like protein-3 (ANGPTL3) to a subject who has atherosclerosis or is at risk of developing atherosclerosis. In certain embodiments, the ANGPTL3 inhibitor is an antibody or antigen-binding fragment thereof that specifically binds ANGPTL3.

Publication date: 2022-03-24
Applicant: Regeneron Pharmaceuticals, Inc.
Inventors: Andrew J Murphy

Publication number: US20220072102A1
Application number: 17/527,956

Abstract:
The present invention provides, among other things, methods of treating post-cardiac injury syndrome (PCIS) or pericarditis, comprising a step of administering to a subject in need of treatment an interleukin-1 receptor-Fc fusion protein at a therapeutically effective dose and an administration interval for a treatment period sufficient to improve, stabilize or reduce one or more signs and symptoms of pericarditis relative to a control.

Publication date: 2022-03-10
Applicant: Regeneron Pharmaceuticals, Inc.
Inventors: John Paolini

How are Regeneron Pharmaceuticals, Inc.’s applications performing in USPTO?

Application Number Title Status Art Unit Examiner
17/618,061 Methods For Removing Undesired Components During Multistage Chromatographic Processes – – –
17/537,275 Methods For Treating Or Preventing Atherosclerosis By Administering An Inhibitor Of Angptl3 Docketed New Case – Ready for Examination OPAP Central, Docket
17/527,956 Treatment Of Inflammatory Conditions By Delivery Of Interleukin-1 Receptor Antagonist Fusion Protein Notice of Allowance Mailed — Application Received in Office of Publications 1646 Li, Ruixiang
17/525,336 Synaptojanin 2 (Synj2) Variants And Uses Thereof Docketed New Case – Ready for Examination OPAP Central, Docket
63/274,595 Methods Of Treating Metabolic Disorders And Cardiovascular Disease With Inhibin Subunit Beta E (Inhbe) Inhibitors – – –